Clinical Trials at Englewood Hospital: Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)
- Please scroll down to view all studies -
EHMC IRB Study #: E-14-543
Dr. Michael Schleider
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.
Patients who are at least 18 years old with newly diagnosed myelodysplastic syndrome (MDS) or 55 years old with newly diagnosed acute myeloid leukemia (AML) are eligible.
To describe current and evolving patterns for diagnosis, treatment, clinical monitoring and outcome measure in patients with high risk or low risk MDS and AML.
Summary of procedures:
Consenting patients will have data entered into the registry at baseline and then on a quarterly basis for up to 8 years, patient withdrawal, or study closure - whichever occurs first.
*Each listing only contains a summary of the study information. Please contact the Principal Investigator or Study Coordinator for the full details on a particular study.